Prelude Therapeutics (PRLD) Operating Income (2019 - 2026)
Prelude Therapeutics (PRLD) posted Operating Income of -$14.2 million for Q1 2026, up 18.28% sequentially from -$17.3 million in Q4 2025, and up 59.03% YoY from -$8.9 million in Q1 2025.
Prelude Therapeutics (PRLD) Operating Income (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Operating Income for 8 years, with the latest figure at -$14.2 million in Q1 2026.
- Quarterly Operating Income rose 59.03% year-over-year to -$14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.1 million (up 39.89% YoY) and the FY2025 annual result came in at -$104.6 million, up 25.16% from the prior year.
- Operating Income advanced to -$14.2 million in Q1 2026 per PRLD's latest filing, from -$17.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$14.2 million in Q1 2026 and troughed at -$37.4 million in Q4 2023.
- A 5-year average of -$30.3 million and a median of -$32.4 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2026: Operating Income plunged 37.88% in 2022, then soared 59.03% in 2026.
- Over 5 years, Operating Income stood at -$33.4 million in 2022, then declined by 11.96% to -$37.4 million in 2023, then gained by 9.49% to -$33.8 million in 2024, then surged by 48.72% to -$17.3 million in 2025, then rose by 18.28% to -$14.2 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$14.2 million, -$17.3 million, and -$20.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | -15.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.45 Mn |
| Mar 31, 2026 | -14.18 Mn |
| Dec 31, 2025 | -17.35 Mn |
| Sep 30, 2025 | -20.42 Mn |
| Jun 30, 2025 | -32.19 Mn |
| Mar 31, 2025 | -34.61 Mn |
| Dec 31, 2024 | -33.83 Mn |
| Sep 30, 2024 | -34.38 Mn |
| Jun 30, 2024 | -37.16 Mn |
| Mar 31, 2024 | -34.34 Mn |
| Dec 31, 2023 | -37.38 Mn |
| Sep 30, 2023 | -33.39 Mn |
| Jun 30, 2023 | -32.40 Mn |
| Mar 31, 2023 | -29.12 Mn |
| Dec 31, 2022 | -33.39 Mn |
| Sep 30, 2022 | -30.41 Mn |
| Jun 30, 2022 | -29.46 Mn |
| Mar 31, 2022 | -30.29 Mn |
| Dec 31, 2021 | -33.01 Mn |
| Sep 30, 2021 | -30.84 Mn |